Sarepta Therapeutics (SRPT) Net Cash Flow (2010 - 2026)

Sarepta Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$336.8 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 60.93% year-over-year to -$336.8 million; the TTM figure through Mar 2026 stood at $221.1 million (up 218.62% YoY), while the FY2025 annual figure was -$304.2 million, down 145.09% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$336.8 million, down from $188.2 million in the prior quarter.
• The five-year high for Net Cash Flow was $905.2 million in Q4 2024, with the low at -$882.0 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$71.8 million (2022), against an average of -$96.9 million.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow jumped 873.16% in 2024, then plunged 75526.58% in 2025.
• Sarepta Therapeutics' Net Cash Flow stood at -$71.8 million in 2022, then plunged by 62.95% to -$117.1 million in 2023, then surged by 873.16% to $905.2 million in 2024, then tumbled by 79.21% to $188.2 million in 2025, then slumped by 278.97% to -$336.8 million in 2026.
• Business Quant data shows SRPT's Net Cash Flow at -$336.8 million in Q1 2026, $188.2 million in Q4 2025, and $100.0 million in Q3 2025.